<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>新浪医药 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-24T20:27:07+08:00</updated>
  <subtitle>新浪医药新闻为医药行业从业者提供新鲜全面的医药资讯、权威的医药政策专家解读、药企药店医院新药新闻资讯动态，以及畅所欲言的专栏平台。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>2020卡瑞利珠单抗总结报告</title>
    <updated>2020-12-24T18:51:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/AWe-eii1B4ujwgAuB244dg</id>
    <link href="https://mp.weixin.qq.com/s/AWe-eii1B4ujwgAuB244dg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百时美施贵宝Opdivo胶质母细胞瘤3期临床错过主要终点</title>
    <updated>2020-12-24T18:51:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/Aa3azacoMEU-2nua0pIV6A</id>
    <link href="https://mp.weixin.qq.com/s/Aa3azacoMEU-2nua0pIV6A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨三款新药纳入CDE拟突破性治疗品种 国药中生新冠肺炎灭活疫苗上市申请获CDE受理</title>
    <updated>2020-12-24T18:51:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/cdYlVCn0jCrL-FsdAUnsuA</id>
    <link href="https://mp.weixin.qq.com/s/cdYlVCn0jCrL-FsdAUnsuA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新冠疫苗玻璃瓶产能不足！中硼还是低硼？</title>
    <updated>2020-12-23T18:27:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-23:/s/-qDaGlAKGJz4423s6FyZdg</id>
    <link href="https://mp.weixin.qq.com/s/-qDaGlAKGJz4423s6FyZdg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>继罗氏、武田之后，Sosei再拿下与葛兰素史克的4.8亿美元合作</title>
    <updated>2020-12-23T18:27:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-23:/s/ZJFQgWk6cAqcxuQZif0utQ</id>
    <link href="https://mp.weixin.qq.com/s/ZJFQgWk6cAqcxuQZif0utQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨FDA批准第二款埃博拉疗法 信达生物阿达木单抗获批两项新适应症</title>
    <updated>2020-12-23T18:27:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-23:/s/dU2hLvj64ydLcE2l0mQq-Q</id>
    <link href="https://mp.weixin.qq.com/s/dU2hLvj64ydLcE2l0mQq-Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济、再鼎、康方纷纷加入，胃癌药物竞争格局不断重塑</title>
    <updated>2020-12-22T18:20:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/tJocdLi2OiDvFY6VSkTKxQ</id>
    <link href="https://mp.weixin.qq.com/s/tJocdLi2OiDvFY6VSkTKxQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年末MNC掀起裁员潮，涉及诺华、赛诺菲、礼来……</title>
    <updated>2020-12-22T18:20:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/NVeaU8kfPqwLsWMsHjYFOQ</id>
    <link href="https://mp.weixin.qq.com/s/NVeaU8kfPqwLsWMsHjYFOQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨阿斯利康PARP抑制剂拟纳入优先审评 东阳光抗丙肝1类新药在中国获批上市</title>
    <updated>2020-12-22T18:20:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-22:/s/O53N662MRbSLpWKj9Ek-OQ</id>
    <link href="https://mp.weixin.qq.com/s/O53N662MRbSLpWKj9Ek-OQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020新浪医药年度总评榜正式揭晓！</title>
    <updated>2020-12-21T13:02:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/2EKDekXWTJSukxHKWysUFw</id>
    <link href="https://mp.weixin.qq.com/s/2EKDekXWTJSukxHKWysUFw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>灵北：新药研发的里程碑源于人性化的企业文化</title>
    <updated>2020-12-21T13:02:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/ixwuJetgHkkZEScIUHH0uQ</id>
    <link href="https://mp.weixin.qq.com/s/ixwuJetgHkkZEScIUHH0uQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新浪医药直播第10课丨借力精准医疗开发全球首创新药</title>
    <updated>2020-12-21T13:02:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/TsQRP1u5_MELhNkKf52Veg</id>
    <link href="https://mp.weixin.qq.com/s/TsQRP1u5_MELhNkKf52Veg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>预测 | 2021年最具商业潜力的上市新药TOP10</title>
    <updated>2020-12-20T18:52:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/gp50M3x4YlXgfPLr6FAQfQ</id>
    <link href="https://mp.weixin.qq.com/s/gp50M3x4YlXgfPLr6FAQfQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>专访恒瑞医药高管王行远：肺癌生存期创新高，卡瑞利珠单抗再现原研之光</title>
    <updated>2020-12-20T18:52:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/annY2349PIjFnfG-PtUgrQ</id>
    <link href="https://mp.weixin.qq.com/s/annY2349PIjFnfG-PtUgrQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨北京一地划为中风险地区，拜耳抗肿瘤1类新药在华获批临床</title>
    <updated>2020-12-20T18:52:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/giJJ4PKTjqPpovjTK25f8Q</id>
    <link href="https://mp.weixin.qq.com/s/giJJ4PKTjqPpovjTK25f8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一周药闻丨赛诺菲/GSK新冠疫苗免疫应答低下，默沙东K药联合卫材LENVIMA治疗子宫内膜癌3期临床成功</title>
    <updated>2020-12-18T23:42:15+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/tJV0mIyTeAGTEw8nzTWoCw</id>
    <link href="https://mp.weixin.qq.com/s/tJV0mIyTeAGTEw8nzTWoCw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>近20年仅上市2款新药，“库欣综合征”临床需求何时才能满足？</title>
    <updated>2020-12-18T18:32:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/aTcNKNZQko59nTTaFGYkUA</id>
    <link href="https://mp.weixin.qq.com/s/aTcNKNZQko59nTTaFGYkUA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新浪医药直播第10课丨借力精准医疗开发全球首创新药</title>
    <updated>2020-12-18T18:32:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/r3qZExRnJ8_VwQr12Z35nA</id>
    <link href="https://mp.weixin.qq.com/s/r3qZExRnJ8_VwQr12Z35nA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>速读社丨K药组合疗法获FDA优先审评资格 三款1类新药拟纳入突破性治疗品种</title>
    <updated>2020-12-18T18:32:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/y-VgVWpeTD_gg5BSHUc0EA</id>
    <link href="https://mp.weixin.qq.com/s/y-VgVWpeTD_gg5BSHUc0EA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>白血病新药吉瑞替尼中国上市在即，安斯泰来选择了与百洋合作</title>
    <updated>2020-12-17T18:15:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/_R-C5ciLZ7EN_L4g2ImxSw</id>
    <link href="https://mp.weixin.qq.com/s/_R-C5ciLZ7EN_L4g2ImxSw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>